🇺🇸 Diphenylcyclopropenone in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 21

Most-reported reactions

1. Drug Ineffective — 4 reports (19.05%)
2. Breast Cancer Recurrent — 3 reports (14.29%)
3. Malignant Neoplasm Progression — 3 reports (14.29%)
4. Metastases To Skin — 3 reports (14.29%)
5. Drug Ineffective For Unapproved Indication — 2 reports (9.52%)
6. Wound Secretion — 2 reports (9.52%)
7. Arthralgia — 1 report (4.76%)
8. Barrett'S Oesophagus — 1 report (4.76%)
9. Blister — 1 report (4.76%)
10. Blood Thyroid Stimulating Hormone Increased — 1 report (4.76%)

Source database →

Frequently asked questions

Is Diphenylcyclopropenone approved in United States?

Diphenylcyclopropenone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Diphenylcyclopropenone in United States?

Rockefeller University is the originator. The local marketing authorisation holder may differ — check the official source linked above.